Breast cancer is classified into different molecular subtypes based on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status, which dictate distinct therapeutic choices and clinical outcomes [1]. This evidence concerns the gene PGR and breast carcinoma.